Skip to main content

Articles

Page 1 of 102

  1. Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival. It is currently not possible to accurately predict who will benefit from the ...

    Authors: Christine Aaserød Pedersen, Maria Dung Cao, Thomas Fleischer, Morten B. Rye, Stian Knappskog, Hans Petter Eikesdal, Per Eystein Lønning, Jörg Tost, Vessela N. Kristensen, May-Britt Tessem, Guro F. Giskeødegård and Tone F. Bathen
    Citation: Breast Cancer Research 2022 24:43
  2. Obesity and adult weight gain are linked to increased breast cancer risk and poorer clinical outcomes in postmenopausal women, particularly for hormone-dependent tumors. Menopause is a time when significant we...

    Authors: Elizabeth A. Wellberg, Karen A. Corleto, L. Allyson Checkley, Sonali Jindal, Ginger Johnson, Janine A. Higgins, Sarina Obeid, Steven M. Anderson, Ann D. Thor, Pepper J. Schedin, Paul S. MacLean and Erin D. Giles
    Citation: Breast Cancer Research 2022 24:42
  3. The majority of BRCA1-mutant breast cancers are characterized by a triple-negative phenotype and a basal-like molecular subtype, associated with aggressive clinical behavior. Current treatment options are limited...

    Authors: Leonie Ratz, Chiara Brambillasca, Leandra Bartke, Maxim A. Huetzen, Jonas Goergens, Orsolya Leidecker, Ron D. Jachimowicz, Marieke van de Ven, Natalie Proost, Bjørn Siteur, Renske de Korte-Grimmerink, Peter Bouwman, Emilia M. Pulver, Roebi de Bruijn, Jörg Isensee, Tim Hucho…
    Citation: Breast Cancer Research 2022 24:41
  4. The Bcl-3 protein is an atypical member of the inhibitor of -κB family that has dual roles as a transcriptional repressor and a coactivator for dimers of NF-κB p50 and p52. Bcl-3 is expressed in mammary adenoc...

    Authors: David Carr, Aiman Zein, Josée Coulombe, Tianqi Jiang, Miguel A. Cabrita, Gwendoline Ward, Manijeh Daneshmand, Andrea Sau and M. A. Christine Pratt
    Citation: Breast Cancer Research 2022 24:40
  5. Chimeric antigen receptor (CAR)-T cells can induce powerful immune responses in patients with hematological malignancies but have had limited success against solid tumors. This is in part due to the immunosupp...

    Authors: Micaela Harrasser, Satyen Harish Gohil, Hiu Lau, Marco Della Peruta, Vincent Muczynski, Dominic Patel, Elena Miranda, Kristiana Grigoriadis, Anita Grigoriadis, David Granger, Rachel Evans and Amit Chunilal Nathwani
    Citation: Breast Cancer Research 2022 24:39
  6. The effect of extracellular microenvironment (hypoxia and pH) has been regarded as a key hallmark in cancer progression. The study aims to investigate the effects of carbonic anhydrase IX (CAIX), a key hypoxia...

    Authors: Chong Hui Clara Ong, Dong Yeul Lee, Bernett Lee, Huihua Li, Jeffrey Chun Tatt Lim, Johnathan Xiande Lim, Joe Poh Sheng Yeong, Hiu Yeung Lau, Aye Aye Thike, Puay Hoon Tan and Jabed Iqbal
    Citation: Breast Cancer Research 2022 24:38
  7. Triple negative breast cancer (TNBC) is an aggressive subtype of invasive breast cancer that disproportionately affects Black women and contributes to racial disparities in breast cancer mortality. Prior resea...

    Authors: Scott D. Siegel, Madeline M. Brooks, Shannon M. Lynch, Jennifer Sims-Mourtada, Zachary T. Schug and Frank C. Curriero
    Citation: Breast Cancer Research 2022 24:37
  8. Up to 60% of breast cancer patients treated with chemotherapy is confronted with cognitive problems, which can have a significant impact on daily activities and quality of life (QoL). We investigated whether e...

    Authors: E. W. Koevoets, S. B. Schagen, M. B. de Ruiter, M. I. Geerlings, L. Witlox, E. van der Wall, M. M. Stuiver, G. S. Sonke, M. J. Velthuis, J. J. Jobsen, M. B. E. Menke-Pluijmers, E. Göker, C. C. van der Pol, M. E. M. M. Bos, L. W. Tick, N. A. van Holsteijn…
    Citation: Breast Cancer Research 2022 24:36
  9. CCR5 is a motility chemokine receptor implicated in tumor progression, whose activation and subsequent endocytosis may identify highly aggressive breast cancer cell subtypes likely to spread into the circulato...

    Authors: Ashvathi Raghavakaimal, Massimo Cristofanilli, Cha-Mei Tang, R. K. Alpaugh, Kirby P. Gardner, Saranya Chumsri and Daniel L. Adams
    Citation: Breast Cancer Research 2022 24:35
  10. PET imaging of 18F-fluorodeoxygucose (FDG) is used widely for tumour staging and assessment of treatment response, but the biology associated with FDG uptake is still not fully elucidated. We therefore carried...

    Authors: G. P. Ralli, R. D. Carter, D. R. McGowan, W.-C. Cheng, D. Liu, E. J. Teoh, N. Patel, F. Gleeson, A. L. Harris, S. R. Lord, F. M. Buffa and J. D. Fenwick
    Citation: Breast Cancer Research 2022 24:34
  11. Breast cancer is uncommon in men and its aetiology is largely unknown, reflecting the limited size of studies thus far conducted. In general, number of children fathered has been found a risk factor inconsiste...

    Authors: Anthony J. Swerdlow, Cydney Bruce, Rosie Cooke, Penny Coulson and Michael E. Jones
    Citation: Breast Cancer Research 2022 24:29
  12. Opioid and beta-adrenergic receptors are recently shown to cross talk via formation of receptor heterodimers to control the growth and proliferation of breast cancer cells. However, the underlying cell signali...

    Authors: Bénédicte Rousseau, Sengottuvelan Murugan, Ajay Palagani and Dipak K. Sarkar
    Citation: Breast Cancer Research 2022 24:33
  13. The interferon response can influence the primary and metastatic activity of breast cancers and can interact with checkpoint immunotherapy to modulate its effects. Using N-ethyl-N-nitrosourea mutagenesis, we foun...

    Authors: Wing-Hong Jonathan Ho, Andrew M. K. Law, Etienne Masle-Farquhar, Lesley E. Castillo, Amanda Mawson, Moira K. O’Bryan, Christopher C. Goodnow, David Gallego-Ortega, Samantha R. Oakes and Christopher J. Ormandy
    Citation: Breast Cancer Research 2022 24:31
  14. Parathyroid hormone-related protein (PTHrP) is required for embryonic breast development and has important functions during lactation, when it is produced by alveolar epithelial cells and secreted into the mat...

    Authors: Diego Y. Grinman, Kata Boras-Granic, Farzin M. Takyar, Pamela Dann, Julie R. Hens, Christina Marmol, Jongwon Lee, Jungmin Choi, Lewis A. Chodosh, Martin E. Garcia Sola and John J. Wysolmerski
    Citation: Breast Cancer Research 2022 24:30
  15. Hormones impact breast tissue proliferation. Studies investigating the associations of circulating hormone levels with mammographic breast density have reported conflicting results. Due to the limited number o...

    Authors: Rachel Mintz, Mei Wang, Shuai Xu, Graham A. Colditz, Chris Markovic and Adetunji T. Toriola
    Citation: Breast Cancer Research 2022 24:28
  16. Mammographic density (MD) phenotypes, including percent density (PMD), area of dense tissue (DA), and area of non-dense tissue (NDA), are associated with breast cancer risk. Twin studies suggest that MD phenot...

    Authors: Hongjie Chen, Shaoqi Fan, Jennifer Stone, Deborah J. Thompson, Julie Douglas, Shuai Li, Christopher Scott, Manjeet K. Bolla, Qin Wang, Joe Dennis, Kyriaki Michailidou, Christopher Li, Ulrike Peters, John L. Hopper, Melissa C. Southey, Tu Nguyen-Dumont…
    Citation: Breast Cancer Research 2022 24:27
  17. Methyltransferase SETDB1 is highly expressed in breast cancer (BC), however, the mechanisms by which SETDB1 promotes BC progression to endocrine therapy resistance remains elusive. In this study, we examined t...

    Authors: Zexuan Liu, Junhao Liu, Behnam Ebrahimi, Uday P. Pratap, Yi He, Kristin A. Altwegg, Weiwei Tang, Xiaonan Li, Zhao Lai, Yidong Chen, Liangfang Shen, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Rajeshwar R. Tekmal, Manjeet K. Rao and Ratna K. Vadlamudi
    Citation: Breast Cancer Research 2022 24:26
  18. Despite advancements in therapies, brain metastasis in patients with triple negative subtype of breast cancer remains a therapeutic challenge. Activated microglia are often observed in close proximity to, or w...

    Authors: Sok Lin Foo, Karishma Sachaphibulkij, Corinne L. Y. Lee, Gracemary L. R. Yap, Jianzhou Cui, Thiruma Arumugam and Lina H. K. Lim
    Citation: Breast Cancer Research 2022 24:25
  19. Multigene panel tests for breast cancer predisposition routinely include ATM as it is now a well-established breast cancer predisposition gene.

    Authors: Anne-Laure Renault, James G. Dowty, Jason A. Steen, Shuai Li, Ingrid M. Winship, Graham G. Giles, John L. Hopper, Melissa C. Southey and Tú Nguyen-Dumont
    Citation: Breast Cancer Research 2022 24:24
  20. PI3K signaling is frequently activated in breast cancer and is targeted by PI3K inhibitors. However, resistance of tumor cells to PI3K inhibition, often mediated by activated receptor tyrosine kinases, is comm...

    Authors: Guus J. J. E. Heynen, Kamil Lisek, Regina Vogel, Annika Wulf-Goldenberg, Joshua Alcaniz, Elodie Montaudon, Elisabetta Marangoni and Walter Birchmeier
    Citation: Breast Cancer Research 2022 24:23
  21. There is an increasing interest in HER2-low breast cancer with promising data from clinical trials using novel anti-HER2 antibody–drug conjugates. We explored the differences in clinicopathological characteris...

    Authors: Hye Sung Won, Juneyoung Ahn, Yongseon Kim, Jin Sung Kim, Jeong-Yoon Song, Hong-Kyu Kim, Jeeyeon Lee, Heung Kyu Park and Yong-Seok Kim
    Citation: Breast Cancer Research 2022 24:22
  22. We recently showed that fucosyltransferase 8 (FUT8)-mediated core fucosylation of transforming growth factor-β receptor enhances its signaling and promotes breast cancer invasion and metastasis. However, the c...

    Authors: Cheng-Fen Tu, Fu-An Li, Ling-Hui Li and Ruey-Bing Yang
    Citation: Breast Cancer Research 2022 24:21
  23. This study investigated the efficacy of radiomics to predict survival outcome for locally advanced breast cancer (LABC) patients and the association of radiomics with tumor heterogeneity and microenvironment.

    Authors: Xuanyi Wang, Tiansong Xie, Jurui Luo, Zhengrong Zhou, Xiaoli Yu and Xiaomao Guo
    Citation: Breast Cancer Research 2022 24:20
  24. While estrogen receptor (ER) positive breast tumors generally respond well to endocrine therapy (ET), up to 40% of patients will experience relapse, either while on endocrine therapy or after ET is completed. ...

    Authors: Svetlana E. Semina, Purab Pal, Nidhi S. Kansara, Rosemary J. Huggins, Elaine T. Alarid, Geoffrey L. Greene and Jonna Frasor
    Citation: Breast Cancer Research 2022 24:19
  25. Resistance to HER2-targeted therapeutics remains a significant clinical problem in HER2+ breast cancer patients with advanced disease. This may be particularly true for HER2+ patients with basal subtype diseas...

    Authors: Moqing Liu, Rebecca Smith, Tiera Liby, Kami Chiotti, Claudia S. López and James E. Korkola
    Citation: Breast Cancer Research 2022 24:18
  26. Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an established standard of care for patients with advanced hormone receptor-positive breast cancer. The canonical mechanism under...

    Authors: April C. Watt and Shom Goel
    Citation: Breast Cancer Research 2022 24:17
  27. Low specificity in current breast imaging modalities leads to increased unnecessary follow-ups and biopsies. The purpose of this study is to evaluate the efficacy of combining the quantitative parameters of hi...

    Authors: Juanjuan Gu, Redouane Ternifi, Nicholas B. Larson, Jodi M. Carter, Judy C. Boughey, Daniela L. Stan, Robert T. Fazzio, Mostafa Fatemi and Azra Alizad
    Citation: Breast Cancer Research 2022 24:16
  28. An increasingly popular measure for summarising cancer prognosis is the loss in life expectancy (LLE), i.e. the reduction in life expectancy following a cancer diagnosis. The proportion of life lost (PLL) can ...

    Authors: Elisavet Syriopoulou, Alessandro Gasparini, Keith Humphreys and Therese M.-L. Andersson
    Citation: Breast Cancer Research 2022 24:15
  29. Improved breast cancer risk assessment models are needed to enable personalized screening strategies that achieve better harm-to-benefit ratio based on earlier detection and better breast cancer outcomes than ...

    Authors: Aimilia Gastounioti, Shyam Desai, Vinayak S. Ahluwalia, Emily F. Conant and Despina Kontos
    Citation: Breast Cancer Research 2022 24:14
  30. Clinical cancer imaging focuses on tumor growth rather than metastatic phenotypes. The microtubule-depolymerizing drug, Vinorelbine, reduced the metastatic phenotypes of microtentacles, reattachment and tumor ...

    Authors: Keyata N. Thompson, Julia A. Ju, Eleanor C. Ory, Stephen J. P. Pratt, Rachel M. Lee, Trevor J. Mathias, Katarina T. Chang, Cornell J. Lee, Olga G. Goloubeva, Patrick C. Bailey, Kristi R. Chakrabarti, Christopher M. Jewell, Michele I. Vitolo and Stuart S. Martin
    Citation: Breast Cancer Research 2022 24:13
  31. Preclinical and epidemiological studies indicate a potential chemopreventive role of low-density lipoprotein cholesterol (LDL-C) -lowering drugs in the risks of breast cancer and prostate cancer, but the causa...

    Authors: Lulu Sun, Huan Ding, Yiming Jia, Mengyao Shi, Daoxia Guo, Pinni Yang, Yu Wang, Fanghua Liu, Yonghong Zhang and Zhengbao Zhu
    Citation: Breast Cancer Research 2022 24:12
  32. Estrogen-receptor (ER) and progesterone-receptor (PR) expression levels in breast cancer, which have been principally compared via binomial descriptors, can vary widely across tumors. We sought to characterize...

    Authors: Grace Wei, Mingxiang Teng, Marilin Rosa and Xia Wang
    Citation: Breast Cancer Research 2022 24:11
  33. Breast cancer can recur months to decades after an initial diagnosis and treatment. The mechanisms that control tumor cell dormancy remain poorly understood, making it difficult to predict which patients will ...

    Authors: Qihao Ren, Weng Hua Khoo, Alexander P. Corr, Tri Giang Phan, Peter I. Croucher and Sheila A. Stewart
    Citation: Breast Cancer Research 2022 24:10
  34. Several anthropometric measures have been associated with hormone-related cancers, and it has been shown that estrogen metabolism in postmenopausal women plays an important role in these relationships. However...

    Authors: Ashley M. Geczik, Roni T. Falk, Xia Xu, Daniel Ansong, Joel Yarney, Beatrice Wiafe-Addai, Lawrence Edusei, Florence Dedey, Verna Vanderpuye, Nicholas Titiloye, Ernest Adjei, Francis Aitpillah, Ernest Osei-Bonsu, Joseph Oppong, Richard Biritwum, Kofi Nyarko…
    Citation: Breast Cancer Research 2022 24:9
  35. Triple-negative breast cancers (TNBC) have a relatively poor prognosis and responses to targeted therapies. Between 25 and 39% of TNBCs are claudin-low, a poorly differentiated subtype enriched for mesenchymal...

    Authors: Yu Hin Tang, Anja Rockstroh, Kamil A. Sokolowski, Layla-Rose Lynam, Melanie Lehman, Erik W. Thompson, Philip A. Gregory, Colleen C. Nelson, Marianna Volpert and Brett G. Hollier
    Citation: Breast Cancer Research 2022 24:8
  36. Keratins (KRTs) are intermediate filament proteins that interact with multiple regulatory proteins to initiate signaling cascades. Keratin 13 (KRT13) plays an important role in breast cancer progression and me...

    Authors: Lijuan Yin, Qinlong Li, Stefan Mrdenovic, Gina Chia-Yi Chu, Boyang Jason Wu, Hong Bu, Peng Duan, Jayoung Kim, Sungyong You, Michael S. Lewis, Gangning Liang, Ruoxiang Wang, Haiyen E. Zhau and Leland W. K. Chung
    Citation: Breast Cancer Research 2022 24:7
  37. Ductal carcinoma in situ (DCIS) of breast is the noninvasive lesion that has propensity to progress to the malignant form. At present, it is still unknown which lesions can potentially progress to invasive for...

    Authors: Ravindra Pramod Deshpande, Sambad Sharma, Yin Liu, Puspa Raj Pandey, Xinhong Pei, Kerui Wu, Shih-Ying Wu, Abhishek Tyagi, Dan Zhao, Yin-Yuan Mo and Kounosuke Watabe
    Citation: Breast Cancer Research 2022 24:6
  38. High participation in mammographic screening is essential for its effectiveness to detect breast cancers early and thereby, improve breast cancer outcomes. Breast density is a strong predictor of breast cancer...

    Authors: Sarah Pirikahu, Helen Lund, Gemma Cadby, Elizabeth Wylie and Jennifer Stone
    Citation: Breast Cancer Research 2022 24:5
  39. Breast cancer incidence differs between non-immigrants and immigrants from low- and middle-income countries. This study investigates whether immigrants also have different subtype-specific incidences.

    Authors: Kirsti V. Hjerkind, Anna L. V. Johansson, Cassia B. Trewin, Hege G. Russnes and Giske Ursin
    Citation: Breast Cancer Research 2022 24:4
  40. Frequent sugar-sweetened beverage (SSB) intake has been associated with indirect markers of breast cancer risk, such as weight gain in adolescents and early menarche. How SSB intake relates to breast compositi...

    Authors: Lara Yoon, Camila Corvalán, Ana Pereira, John Shepherd and Karin B. Michels
    Citation: Breast Cancer Research 2022 24:3
  41. Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants have differential associations by estrogen receptor (ER) status, but how the...

    Authors: Thomas U. Ahearn, Haoyu Zhang, Kyriaki Michailidou, Roger L. Milne, Manjeet K. Bolla, Joe Dennis, Alison M. Dunning, Michael Lush, Qin Wang, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Kristan J. Aronson, Paul L. Auer, Annelie Augustinsson, Adinda Baten…
    Citation: Breast Cancer Research 2022 24:2
  42. A growing body of evidence indicates that abnormal expression of circular RNAs (circRNAs) plays a crucial role by acting as molecular sponges of microRNAs (miRNAs) in various diseases, including cancer. In thi...

    Authors: Lingjiao Meng, Sheng Chang, Yang Sang, Pingan Ding, Liuxin Wang, Xixi Nan, Ruiyu Xu, Fei Liu, Lina Gu, Yang Zheng, Ziyi Li and Meixiang Sang
    Citation: Breast Cancer Research 2022 24:1
  43. The first aim of the study was to compare the scores and types of stromal immune cells in 30 patients with primary DCIS and in the same patients after invasive breast recurrence in order to assess possible dif...

    Authors: Anna Niwińska and Wojciech P. Olszewski
    Citation: Breast Cancer Research 2021 23:118
  44. The active thyroid hormone triiodothyronine (T3) has been found to have an estrogen-like effect on breast cancer cells. Thyroid hormone receptor alpha-2 (THRα-2) acts as an antagonist for triiodothyronine (T3)...

    Authors: Malte Sandsveden, Signe Borgquist, Ann H. Rosendahl and Jonas Manjer
    Citation: Breast Cancer Research 2021 23:117
  45. Triple-negative breast cancer (TNBC) is highly metastatic and lethal. Due to a lack of druggable targets for this disease, there are no effective therapies in the clinic.

    Authors: Mengli Zhang, Mei Meng, Yuxi Liu, Jindan Qi, Zhe Zhao, Yingnan Qiao, Yanxing Hu, Wei Lu, Zhou Zhou, Peng Xu and Quansheng Zhou
    Citation: Breast Cancer Research 2021 23:116
  46. Mounting evidence supports that long noncoding RNAs (lncRNAs) have critical roles during cancer initiation and progression. In this study, we report that the plasmacytoma variant translocation 1 (PVT1) lncRNA ...

    Authors: Shuiyi Liu, Weiqun Chen, Hui Hu, Tianzhu Zhang, Tangwei Wu, Xiaoyi Li, Yong Li, Qinzhi Kong, Hongda Lu and Zhongxin Lu
    Citation: Breast Cancer Research 2021 23:115
  47. The extent of cellular heterogeneity in breast cancer could have potential impact on diagnosis and long-term outcome. However, pathology evaluation is limited to biomarker immunohistochemical staining and morp...

    Authors: Alison Min-Yan Cheung, Dan Wang, Kela Liu, Tyna Hope, Mayan Murray, Fiona Ginty, Sharon Nofech-Mozes, Anne Louise Martel and Martin Joel Yaffe
    Citation: Breast Cancer Research 2021 23:114
  48. Triple negative breast cancer (TNBC) is more common in African American (AA) than Non-AA (NAA) population. We hypothesize that tumor microenvironment (TME) contributes to this disparity. Here, we use multiplex...

    Authors: Vesal Yaghoobi, Myrto Moutafi, Thazin Nwe Aung, Vasiliki Pelekanou, Sanam Yaghoubi, Kim Blenman, Eiman Ibrahim, Ioannis A. Vathiotis, Saba Shafi, Anup Sharma, Tess O’Meara, Aileen I. Fernandez, Lajos Pusztai and David L. Rimm
    Citation: Breast Cancer Research 2021 23:113

Annual Journal Metrics